Crossmark

Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy

Crossref DOI link: https://doi.org/10.1007/s40291-018-0354-8

Published Online: 2018-08-03

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Galluzzo, Marco https://orcid.org/0000-0002-3424-5175
D’Adamio, Simone

Campione, Elena

Bianchi, Luca

Talamonti, Marina
License Information

Text and Data Mining valid from 2018-08-03
More Information

Article History

First Online: 3 August 2018

Compliance with Ethical Standards

:

: L Bianchi has served as a speaker and consultant for AbbVie, Novartis, Janssen-Cilag, Pfizer, UCB, and Leo-Pharma outside the submitted work. MG, SDA, EC, and MT have no conflicts of interest.

: No sources of funding were used to conduct this study or prepare this manuscript.

: This study was conducted in accordance with the Helsinki Declaration. The patient gave written informed consent to draw a vial of blood for DNA analyses as approved by the Tor Vergata Ethics Committee (approval no. 20745, v. 25 Mar 2005).